Viridian Therapeutics (VRDN)
(Delayed Data from NSDQ)
$13.47 USD
-1.37 (-9.23%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $13.48 +0.01 (0.07%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Viridian Therapeutics, Inc. (VRDN) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$34.93 | $46.00 | $20.00 | 135.38% |
Price Target
Based on short-term price targets offered by 15 analysts, the average price target for Viridian Therapeutics, Inc. comes to $34.93. The forecasts range from a low of $20.00 to a high of $46.00. The average price target represents an increase of 135.38% from the last closing price of $14.84.
Analyst Price Targets (15)
Broker Rating
Viridian Therapeutics, Inc. currently has an average brokerage recommendation (ABR) of 1.27 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms. The current ABR compares to an ABR of 1.38 a month ago based on 16 recommendations.
Of the 15 recommendations deriving the current ABR, 12 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 80% and 13.33% of all recommendations. A month ago, Strong Buy made up 75%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 12 | 12 | 12 | 12 | 12 |
Buy | 2 | 2 | 2 | 2 | 2 |
Hold | 1 | 1 | 2 | 2 | 2 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.27 | 1.27 | 1.38 | 1.38 | 1.38 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/30/2024 | Needham & Company | Serge Belanger | Moderate Buy | Moderate Buy |
8/12/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/9/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
8/8/2024 | SVB Securities | Thomas J Smith | Strong Buy | Strong Buy |
7/29/2024 | Wedbush Securities | Laura Chico | Strong Buy | Strong Buy |
7/16/2024 | H.C. Wainwright & Co. | Douglas Tsao | Strong Buy | Strong Buy |
6/11/2024 | LifeSci Capital | Rami Katkhuda | Strong Buy | Strong Buy |
6/11/2024 | Not Identified | Not Identified | Not Available | Strong Buy |
6/6/2024 | Goldman Sachs | Richard Law | Not Available | Strong Buy |
5/9/2024 | B. Riley Securities | Kalpit Patel | Strong Buy | Hold |
5/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/15/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
2/28/2024 | Wells Fargo Securities | Derek C Archila | Strong Buy | Strong Buy |
2/1/2024 | BTIG | Julian Harrison | Strong Buy | Strong Buy |
11/14/2023 | JMP Securities | Jason N Butler | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.27 |
ABR (Last week) | 1.27 |
# of Recs in ABR | 15 |
Average Target Price | $34.93 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 253 |
Current Quarter EPS Est: | -1.10 |
VRDN FAQs
Viridian Therapeutics, Inc. (VRDN) currently has an average brokerage recommendation (ABR) of 1.27 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 15 brokerage firms.
The average price target for Viridian Therapeutics, Inc. (VRDN) is $34.93. The current on short-term price targets is based on 8 reports.
The forecasts for Viridian Therapeutics, Inc. (VRDN) range from a low of $20 to a high of $46. The average price target represents a increase of $159.32 from the last closing price of $13.47.
The current UPSIDE for Viridian Therapeutics, Inc. (VRDN) is 159.32%
Based on short-term price targets offered by 15 analysts, the average price target for Viridian Therapeutics, Inc. comes to $34.93. The forecasts range from a low of $20.00 to a high of $46.00. The average price target represents an increase of 135.38% from the last closing price of $14.84.